Infographic from the GRADE study comparing the effectiveness of glucose-lowering medications on glycemic reduction and metabolic parameters over time. Includes charts showing patient randomization, fasting glucose levels, glucose control over time, and HbA1c outcomes.

The effect of #glimepiride, #insulin #glargine, #liraglutide or #sitagliptin on the islet #α-cell does not impact glycemia progression in type 2 #diabetes, whereas their effect on the #β-cell does.

Read here ➡️ doi.org/10.2337/dc25-2186

Weekly fixed-dose basal insulin noninferior to glargine for type 2 diabetes control Once-weekly, fixed-dose insulin efsitora has been found noninferior to insulin glargine at reducing glycated hemoglobin levels in people with type 2 diabetes.

From #ADA2025 - Once-weekly, fixed-dose insulin #efsitora has been found noninferior to insulin #glargine at reducing glycated hemoglobin levels in people with #T2D.

Full story 👉 buff.ly/xjwKO77

#MedNews #Insulin